医学
伊克泽珠单抗
塞库金单抗
免疫学
炎症
细胞因子
促炎细胞因子
银屑病
银屑病性关节炎
作者
Ajay Nirula,Jon Nilsen,Paul Klekotka,Greg Kricorian,Ngozi Erondu,Jennifer E. Towne,Chris B. Russell,David A. Martin,Alison Budelsky
出处
期刊:Rheumatology
[Oxford University Press]
日期:2016-10-11
卷期号:55 (suppl 2): ii43-ii55
被引量:56
标识
DOI:10.1093/rheumatology/kew346
摘要
IL-17 cytokines are expressed by a variety of cells and mediate host defence against extracellular pathogens. IL-17 is upregulated at sites of inflammation and can synergize with other cytokines, such as TNF-α, to amplify the inflammatory response. Activation of these signalling pathways has been hypothesized to contribute to the underlying pathogenesis of several inflammatory diseases, including psoriasis, RA, PsA and asthma. Thus the IL-17 signalling pathway is an attractive target for the development of therapeutic agents to modulate aberrant inflammatory responses. This review of the clinical development of therapeutic agents that target IL-17 signalling pathways in inflammatory diseases focuses on brodalumab, a human anti-IL-17 receptor A mAb. The cumulative findings of early clinical studies with anti-IL-17 agents, including brodalumab, secukinumab and ixekizumab, provide strong evidence for the role of IL-17 signalling in the pathophysiology of certain inflammatory diseases and support the potential use of these agents in treating these diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI